TVTX Travere Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1438533 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY49.4%
TTM net income YoY-37.2%
TTM EPS YoY-26.2%
Revenue 3-yr CAGR71.3%
Net income 3-yr CAGR—
Margins
Gross margin98.5%
Operating margin-20.5%
Net margin-18.7%
FCF margin—
EBITDA margin-12.4%
Returns
ROE-252.7%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets97.3%
Debt / equity0.00x
Current ratio3.00x
Interest coverage-15.05x
Cash quality & payout
Operating cash flow / net income-1.54x
Accruals ratio-44.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $490.73M | $233.18M |
| Cost of revenue | $10.34M | $7.74M |
| Gross profit | $480.39M | $225.43M |
| R&D expense | $206.01M | $217.50M |
| SG&A expense | $337.20M | $264.12M |
| Operating income | -$62.82M | -$323.83M |
| Interest expense | $10.75M | $11.18M |
| Pretax income | -$49.27M | -$320.51M |
| Income tax | $988,000 | $120,000 |
| Net income | -$25.55M | -$321.55M |
| EBITDA | -$2.08M | -$280.27M |
| EPS (basic) | -0.29 | -4.08 |
| EPS (diluted) | -0.29 | -4.08 |
| Weighted avg. shares (diluted) | 89.21M | 78.89M |
| Balance sheet | ||
| Cash & equivalents | $93.03M | $58.53M |
| Short-term investments | $145.38M | — |
| Receivables | $80.13M | $27.12M |
| Inventory | $36.16M | $41.86M |
| Current assets | $437.56M | $416.70M |
| PP&E, net | $4.02M | $5.34M |
| Goodwill | — | $800,000 |
| Intangibles | $113.87M | $103.97M |
| Total assets | $605.19M | $594.12M |
| Current liabilities | $159.90M | $200.75M |
| Total liabilities | $490.36M | $535.05M |
| Shareholders' equity | $114.83M | $59.08M |
| Shares outstanding | 90.92M | 87.45M |
| Cash flow statement | ||
| Operating cash flow | $37.78M | -$237.47M |
| Investing cash flow | $27.89M | $99.33M |
| Financing cash flow | -$33.47M | $139.42M |
| Depreciation & amortization | $60.74M | $43.55M |
| Stock-based compensation | $44.87M | $36.91M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.